Safety and efficacy of generic drugs with respect to brand formulation.
about
A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic)Recurrence of atrial fibrillation after switching from brand to generic atenololComparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations.Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.
P2860
Safety and efficacy of generic drugs with respect to brand formulation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and efficacy of generic drugs with respect to brand formulation.
@en
Safety and efficacy of generic drugs with respect to brand formulation.
@nl
type
label
Safety and efficacy of generic drugs with respect to brand formulation.
@en
Safety and efficacy of generic drugs with respect to brand formulation.
@nl
prefLabel
Safety and efficacy of generic drugs with respect to brand formulation.
@en
Safety and efficacy of generic drugs with respect to brand formulation.
@nl
P2093
P2860
P356
P1476
Safety and efficacy of generic drugs with respect to brand formulation
@en
P2093
Antonio De Vuono
Brunella Piro
Caterina Palleria
Laura Mumoli
Luca Gallelli
Piero Vasapollo
P2860
P304
P356
10.4103/0976-500X.120972
P433
P50
P577
2013-12-01T00:00:00Z